1. Signifor [prescribing information] East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2015.
2. Colao A, Petersenn S, Newell-Price J, et al. A 12-Month Phase 3 Study of Pasireotide in Cushing`s Disease. N Engl J Med 2012;366:914-24.
3. Biller BM, Grossman AB, Stewart PM, et al. Treatment of Adrenocorticotropin-Dependent Cushing`s Syndrome: A Consensus Statement. J Clin Endocrinol Metab. July 2008, 93(7):2454-2462.
4. Micromedex Healthcare Series [Internet Database]. Greenwood, Colo: Thomson Reuters (Healthcare) Inc. Updated periodically. Accessed June 29, 2015.
5. Pasireotide. American Hospital Formulary Service Drug Information. Available at http://www.medicinescomplete.com/mc/ahfs/current/. Accessed June 29, 2015.
6. Signifor LAR [prescribing information] Basel, Switzerland: Novartis Pharma AG; December 2014.
7. Giustina A, Chanson P, Melmed S, et al. Expert consensus document: A consensus on the medical treatment of acromegaly. Nat Rev Endocrinol 2014 Apr;10(4):243-8. Available at: www.nature.com/nrendo/journal/v10/n4/full/nrendo.2014.21.html